STAAR Surgical (NASDAQ:STAA) has earned an average rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $39.00.

A number of research analysts recently weighed in on STAA shares. TheStreet upgraded shares of STAAR Surgical from a “c+” rating to a “b” rating in a report on Tuesday. Zacks Investment Research cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, April 16th. Stephens dropped their price objective on shares of STAAR Surgical from $56.00 to $37.00 and set an “overweight” rating for the company in a report on Monday, March 23rd. Canaccord Genuity restated a “buy” rating on shares of STAAR Surgical in a report on Thursday, May 7th. Finally, ValuEngine cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, March 17th.

STAAR Surgical stock opened at $37.86 on Wednesday. The company’s 50 day simple moving average is $35.17 and its 200-day simple moving average is $34.88. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of 140.23 and a beta of 1.65. STAAR Surgical has a 1 year low of $22.84 and a 1 year high of $42.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.17 and a current ratio of 5.75.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $35.19 million during the quarter, compared to analysts’ expectations of $34.90 million. STAAR Surgical had a net margin of 8.21% and a return on equity of 12.52%. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. Equities analysts expect that STAAR Surgical will post 0.45 earnings per share for the current year.

In related news, VP Jon K. Hayashida sold 2,813 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $26.83, for a total value of $75,472.79. Following the completion of the sale, the vice president now owns 13,607 shares in the company, valued at approximately $365,075.81. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Jon K. Hayashida sold 46,563 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $39.11, for a total transaction of $1,821,078.93. Following the completion of the sale, the vice president now owns 32,088 shares of the company’s stock, valued at approximately $1,254,961.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 77,118 shares of company stock valued at $2,913,987. Company insiders own 4.30% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. raised its position in STAAR Surgical by 2.4% in the 4th quarter. Advisors Asset Management Inc. now owns 12,429 shares of the medical instruments supplier’s stock valued at $437,000 after purchasing an additional 294 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in STAAR Surgical by 68.5% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 935 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 380 shares during the last quarter. Amalgamated Bank raised its position in STAAR Surgical by 5.2% during the 4th quarter. Amalgamated Bank now owns 8,349 shares of the medical instruments supplier’s stock worth $294,000 after buying an additional 410 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in STAAR Surgical during the 4th quarter worth $4,396,000. Finally, US Bancorp DE raised its position in STAAR Surgical by 24.0% during the 4th quarter. US Bancorp DE now owns 2,883 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 558 shares during the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

See Also: Should You Consider an Index Fund?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.